

OPEN ACCESS

EDITED AND REVIEWED BY
Luisa Lanfrancone,
European Institute of Oncology (IEO), Italy

*CORRESPONDENCE

Bei Lin

Iinbei88@hotmail.com;

prof_linbei@126.com

RECEIVED 18 July 2024 ACCEPTED 04 November 2024 PUBLISHED 03 December 2024

CITATION

Guo Q, Zhu L, Wang C, Wang S, Nie X, Liu J, Liu Q, Hao Y, Li X and Lin B (2024) Corrigendum: SERPIND1 affects the malignant biological behavior of epithelial ovarian cancer via the PI3K/AKT pathway: a mechanistic study. *Front. Oncol.* 14:1466959. doi: 10.3389/fonc.2024.1466959

COPYRIGHT

© 2024 Guo, Zhu, Wang, Wang, Nie, Liu, Liu, Hao, Li and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: SERPIND1 affects the malignant biological behavior of epithelial ovarian cancer via the PI3K/AKT pathway: a mechanistic study

Qian Guo^{1,2,3}, Liancheng Zhu¹, Caixia Wang¹, Shuang Wang¹, Xin Nie¹, Juanjuan Liu¹, Qing Liu¹, Yingying Hao¹, Xiao Li¹ and Bei Lin^{1,2,3}*

¹Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China, ²Key Laboratory of Maternal-Fetal Medicine of Liaoning Province, Benxi, China, ³Key Laboratory of Obstetrics and Gynecology of Higher Education of Liaoning Province, Benxi, China

KEYWORDS

epithelial ovarian cancer, SERPIND1, prognosis, proliferation, cell cycle, cell migration, EMT, NF- κ B1

A Corrigendum on

SERPIND1 affects the malignant biological behavior of epithelial ovarian cancer via the PI3K/AKT pathway: a mechanistic study

By Guo Q, Zhu L, Wang C, Wang S, Nie X, Liu J, Liu Q, Hao Y, Li X and Lin B (2019). *Front. Oncol.* 9:954. doi: 10.3389/fonc.2019.00954

In the published article, there was an error in **Figure 2B** as published. The image for panel (8) was incorrectly placed, resulting in a repetition of the image for panel (7). Consequently, both panels (7) and (8) show the OVCAR3 transwell image, while the OVCAR3-SERPIND1-L-Mock transwell image was not included in the correct position. The correct content should have panel (7) showing the OVCAR3 transwell image and panel (8) showing the blank control OVCAR3-SERPIND1-L-Mock transwell image. This was entirely an inadvertent error due to the similar naming of the images, leading to the incorrect image being used. The corrected **Figure 2B** and its caption appear below.


The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Guo et al. 10.3389/fonc.2024.1466959

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



Effects of SERPIND1 on ovarian cancer cells *in vitro*. (A) SERPIND1 promoted the migration capacity of ovarian cancer cells. (B) SERPIND1 promoted the invasion capacity of ovarian cancer cells. (C) SERPIND1 inhibited apoptosis in ovarian cancer cell lines. (D) Effects of SERPIND1 on the cell cycle of ovarian cancer cell lines. (E) SERPIND1 promoted the proliferation of ovarian cancer cells. (1): ES-2; (2): ES-2-SERPIND1-H-Mock; (3): ES-2-SERPIND1-H; (4): CAOV3; (5): CAOV3-SERPIND1-L- Mock; (6): CAOV3-SERPIND1-L; (7): OVCAR3; (8): OVCAR3-SERPIND1-L- Mock (9): OVCAR3-SERPIND1-L. Data are presented as mean \pm standard deviation from three independent experiments. *P < 0.05. Scale bar: 100 μ m. SERPIND1, serpin family D member 1.